Short Interest in Mustang Bio, Inc. (NASDAQ:MBIO) Drops By 39.2%

Mustang Bio, Inc. (NASDAQ:MBIO) saw a large decrease in short interest in the month of February. As of February 27th, there was short interest totaling 133,993 shares, a decrease of 39.2% from the February 12th total of 220,214 shares. Based on an average trading volume of 37,451 shares, the short-interest ratio is currently 3.6 days. Currently, 1.9% of the shares of the stock are short sold. Currently, 1.9% of the shares of the stock are short sold. Based on an average trading volume of 37,451 shares, the short-interest ratio is currently 3.6 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Mustang Bio in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Hedge Funds Weigh In On Mustang Bio

A hedge fund recently raised its stake in Mustang Bio stock. Kestra Advisory Services LLC boosted its stake in Mustang Bio, Inc. (NASDAQ:MBIO) by 68.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 111,042 shares of the company’s stock after acquiring an additional 44,934 shares during the period. Kestra Advisory Services LLC owned 1.52% of Mustang Bio worth $109,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 9.95% of the company’s stock.

Mustang Bio Stock Down 0.3%

Shares of MBIO stock traded down $0.00 during mid-day trading on Friday, reaching $0.94. 27,737 shares of the stock traded hands, compared to its average volume of 39,102. The company has a market cap of $6.88 million, a price-to-earnings ratio of -3.04 and a beta of 2.13. The stock’s fifty day simple moving average is $0.97 and its two-hundred day simple moving average is $1.23. Mustang Bio has a 1-year low of $0.53 and a 1-year high of $7.00.

About Mustang Bio

Mustang Bio, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies for oncology and rare genetic diseases. The company’s primary platform leverages chimeric antigen receptor T‐cell (CAR-T) technology to target both hematologic and solid tumor indications. In parallel, Mustang Bio is advancing a portfolio of lentiviral‐based gene therapy candidates designed to address inherited metabolic disorders with high unmet medical need.

The company’s oncology pipeline includes programs directed at B-cell malignancies and aggressive brain tumors, with lead CAR-T candidates in clinical trials for glioblastoma multiforme and various B-cell leukemias and lymphomas.